



## **PENTASA® Available in Oral and Rectal Formats**

PENTASA® (mesalazine) extended release tablets are indicated for:

- Treatment of mild to moderate active ulcerative colitis and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease.

PENTASA® is available in **three distinct dosing forms:**

### **PENTASA® Oral:**

- **1 g** extended-release oral tablet  
(UPC: 779170555800)
- **500 mg** extended-release oral tablet  
(UPC: 779170555701)

### **PENTASA® Rectal:**

- **1 g** rectal suppository  
(UPC: 779170555220)

### **PENTASA® Enema:**

- **1 g** enema  
(UPC: 779170151002)
- **4 g** enema  
(UPC: 779170154003)

**Consider PENTASA® for appropriate patients and refer to the PENTASA® Product Monograph for further information.**

Product Monograph available upon request.  
Toronto, ON, M2J 5C1. 1-866-384-1314  
2020 Ferring Inc. All rights reserved.  
PENTASA® is a registered trade mark of Ferring B.V.

CA-PA-2000004



## PENTASA® Oral Tablets Reminder

Ferring Pharmaceuticals would like to remind you that the PENTASA® oral tablets are now packaged in blister formats.



Packaging Details	UPC	Size/Format
PENTASA® 1 g Tablet 60's	779170555800	60 Tablets (10 tablets per blister, 6 blisters in carton)

Product Monograph available upon request.  
Toronto, ON, M2J 5C1. 1-866-384-1314  
2020 Ferring Inc. All rights reserved.  
PENTASA® is a registered trade mark of Ferring B.V.

CA-PA-2000004